Pharmaceutical

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Sep 5, 2023 - 20:00
Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer
Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.
Read the original article

Tags:

Previous Article

STAT+: Lawmakers call on FDA to issue stricter bone graft guidance

Next Article

Direct oral anticoagulants’ positive effects on cancer-associated VTE

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rani reports positive data for non-injectable Stelara biosimilar

Rani reports positive data for non-injectable Stelara b...

Feb 6, 2024

STAT+: Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa

STAT+: Alkermes shareholders re-elect directors, rebuff...

Jun 30, 2023

CMN-005 by CoImmune for B-Cell Non-Hodgkin Lymphoma: Li...

Sep 10, 2024